Veliparib

also known as ABT-888 · ABT-888, veliparib · NSC 737664 · PARP-1 INHIBITOR ABT-888 · UNII-01O4K0631N · Veliparib (ABT-888)

Small molecule targets PARP1 via inhibition

Developed for: triple-negative breast carcinoma · breast cancer · ovarian cancer · primary peritoneal carcinoma · BRCA1-related cancer predisposition · BRCA2-related cancer predisposition · cancer · ovarian carcinoma
+172 more
· fallopian tube carcinoma · neoplasm · non-small cell lung carcinoma · colorectal cancer · female breast carcinoma · small cell lung carcinoma · cancer of unknown primary site · chronic myelomonocytic leukemia · fallopian tube cancer · gastric cancer · hereditary breast carcinoma · lymphoma · male breast carcinoma · metastatic malignant neoplasm · pancreatic adenocarcinoma · acquired polycythemia vera · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myeloid leukemia, t(8;21)(q22; q22.1) · acute myeloid leukemia, t(9;11)(p21.3;q23.3) · anaplastic astrocytoma · B-cell adult acute lymphocytic leukemia · brain stem glioma · breast carcinoma · central nervous system neoplasm · cervical adenosquamous carcinoma · essential thrombocythemia · gliosarcoma · hepatocellular carcinoma · hereditary breast ovarian cancer syndrome · lung cancer · lung large cell carcinoma · malignant pancreatic neoplasm · mantle cell lymphoma · mixed glioma · ovarian endometrioid adenocarcinoma · ovarian serous adenocarcinoma · plasma cell myeloma · undifferentiated ovarian carcinoma · acute megakaryoblastic leukemia in adult · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia · acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia, t(15;17)(q24;q21) · acute myelomonocytic leukemia M4 · adrenal cortex carcinoma · adult acute lymphoblastic leukemia · adult acute monocytic leukemia · adult T-cell leukemia/lymphoma · anaplastic large cell lymphoma · angioimmunoblastic T-cell lymphoma · astrocytoma (excluding glioblastoma) · atypical chronic myeloid leukemia, BCR-ABL1 negative · atypical teratoid rhabdoid tumor · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · basal-like breast carcinoma · benign meningioma · bladder transitional cell carcinoma · brain neoplasm · Burkitt lymphoma · carcinoma of esophagus · castration-resistant prostate carcinoma · cervical small cell carcinoma · childhood brain stem glioma · childhood central nervous system germ cell tumor · childhood cerebellar astrocytic neoplasm · childhood cerebral astrocytoma · childhood choroid plexus neoplasm · childhood medulloblastoma · childhood oligodendroglioma · childhood spinal cord tumor · chronic lymphocytic leukemia/small lymphocytic lymphoma · chronic myeloid leukemia · craniopharyngioma · cutaneous neuroendocrine carcinoma · endometrial carcinoma · ependymoblastoma · ependymoma · erythroleukemia · estrogen-receptor positive breast cancer · extrahepatic bile duct carcinoma · extranodal nasal NK/T cell lymphoma · fallopian tube carcinosarcoma · fallopian tube clear cell adenocarcinoma · fallopian tube endometrioid adenocarcinoma · fallopian tube mucinous adenocarcinoma · fallopian tube transitional cell carcinoma · gallbladder carcinoma · gastric adenocarcinoma · glioblastoma · glucagonoma · grade II meningioma · grade III lymphomatoid granulomatosis · grade III meningioma · hairy cell leukemia · head and neck cancer · head and neck squamous cell carcinoma · hepatosplenic T-cell lymphoma · hereditary neoplastic syndrome · high grade malignant neoplasm · Hodgkin's lymphoma, mixed cellularity · intraocular lymphoma · large-cell immunoblastic lymphoma · leukemia · lung carcinoma · malignant adrenal gland pheochromocytoma · malignant epithelial tumor of ovary · MALT lymphoma · medullary thyroid gland carcinoma · medulloblastoma · medulloepithelioma · melanoma · metastatic malignant neoplasm in the brain · metastatic melanoma · metastatic neoplasm · minimally invasive lung adenocarcinoma · multiple endocrine neoplasia type 1 · multiple endocrine neoplasia type 2A · multiple endocrine neoplasia type 2B · mycosis fungoides and variants · myelodysplastic syndrome · myelofibrosis · nodal marginal zone B-cell lymphoma · non-functional pancreatic neuroendocrine tumor · non-small cell squamous lung carcinoma · optic pathway glioma · oropharyngeal carcinoma · ovarian Brenner tumor · ovarian carcinosarcoma · ovarian clear cell adenocarcinoma · ovarian clear cell cystadenocarcinoma · ovarian germ cell tumor · ovarian mucinous adenocarcinoma · ovarian mucinous cystadenocarcinoma · ovarian seromucinous carcinoma · ovarian seromucinous tumor · ovarian serous cystadenocarcinoma · ovarian transitional cell carcinoma · pancreas disorder · pancreatic insulinoma · pediatric infratentorial ependymoma · pediatric supratentorial ependymoma · peritoneal carcinomatosis · pineoblastoma · primary cutaneous B-cell lymphoma · primary organ-specific lymphoma · primary peritoneal serous adenocarcinoma · primitive neuroectodermal tumor · prostate cancer · prostate carcinoma · rectal carcinoma · rectum adenocarcinoma · renal pelvis/ureter urothelial carcinoma · serous adenocarcinoma · small intestine lymphoma · somatostatinoma · splenic marginal zone lymphoma · squamous cell lung carcinoma · subependymal giant cell astrocytoma · supratentorial primitive neuroectodermal tumor · T-cell adult acute lymphocytic leukemia · T-cell non-Hodgkin lymphoma · testicular cancer · testicular germ cell tumor · testicular lymphoma · thymic neuroendocrine tumor · urothelial carcinoma · VIPoma · Waldenstrom macroglobulinemia · Zollinger-Ellison syndrome
Investigated by: National Cancer Institute (NCI) · AbbVie · Abbott · NRG Oncology · Georgetown University · University of Washington
+29 more
· Vejle Hospital · AHS Cancer Control Alberta · Australia New Zealand Gynaecological Oncology Group · Beth Israel Deaconess Medical Center · Breast Cancer Research Foundation of Alabama · Bristol-Myers Squibb · Cedars-Sinai Medical Center · Central European Society for Anticancer Drug Research · Children's Oncology Group · Dana-Farber Cancer Institute · Dutch Cancer Society · GlaxoSmithKline · National Cancer Institute, Slovakia · National Institutes of Health Clinical Center (CC) · Northwestern University · Prostate Cancer Clinical Trials Consortium · QuantumLeap Healthcare Collaborative · Radiation Therapy Oncology Group · Richard Zellars · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Steven J Isakoff, MD, PhD · Susan G. Komen Breast Cancer Foundation · The University of Texas Health Science Center at San Antonio · Tom Baker Cancer Centre · University Medical Center Groningen · University of Alabama at Birmingham · University of Michigan Rogel Cancer Center · Vanderbilt-Ingram Cancer Center

Trials 99 · started per year

today

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 153 trials · 2 met primary
Phase 1	NCT03400306	Nov 2021	ovarian cancer	AbbVie	Withdrawn	No outcome recorded Stop: Business
Phase 1	NCT02831179	Dec 2017 → Feb 2019	VIPoma, Zollinger-Ellison syndrome, adrenal cortex carcinoma, cutaneous neuroendocrine carcinoma +10	Vanderbilt-Ingram Cancer Center	Withdrawn	No outcome recorded Stop: Business
Phase 1	NCT02723864	Aug 2017 → Dec 2020	neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT02631733	May 2017 → Nov 2019	cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT03061188	May 2017 → Mar 2018	T-cell non-Hodgkin lymphoma, high grade malignant neoplasm, mantle cell lymphoma	Northwestern University	Completed	No outcome recorded
Phase 1	NCT02944396	Dec 2016 → Oct 2019	non-small cell lung carcinoma	AbbVie	Completed	No outcome recorded
Phase 1	NCT03227016	Oct 2016 → May 2021	small cell lung carcinoma	Central European Society for Anticancer Drug Research	Unknown	No outcome recorded
Phase 1	NCT02483104	Jul 2015 → Mar 2016	ovarian cancer	AbbVie	Completed	No outcome recorded
Phase 1	NCT02210663	Jul 2014 → Jan 2016	cancer	AbbVie	Completed	No outcome recorded
Phase 1	NCT02033551	Dec 2013 → Sep 2016	breast cancer, colorectal cancer, gastric cancer, lung cancer +1	AbbVie	Completed	No outcome recorded
Phase 1	NCT02009631	Nov 2013 → Dec 2014	breast cancer, colorectal cancer, gastric cancer, lung cancer +1	AbbVie	Completed	Met primary
Phase 1	NCT01908478	Oct 2013 → Jul 2017	malignant pancreatic neoplasm	Cedars-Sinai Medical Center	Completed	No outcome recorded
Phase 1	NCT01618357	Jul 2013 → Sep 2023	breast cancer	Richard Zellars	Completed	No outcome recorded
Phase 1	NCT01853306	Mar 2013 → May 2017	hereditary breast carcinoma, hereditary neoplastic syndrome, ovarian serous adenocarcinoma	AbbVie	Completed	No outcome recorded
Phase 1	NCT01749397	Dec 2012 → Oct 2017	fallopian tube cancer, primary peritoneal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01589419	Jun 2012 → Jan 2015	—	AbbVie	Completed	No outcome recorded
Phase 1	NCT01617928	May 2012 → Jul 2013	cancer	AbbVie	Completed	No outcome recorded
Phase 1	NCT01477489	Jan 2012 → Oct 2014	breast cancer	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
Phase 1	NCT01434316	Nov 2011 → Mar 2023 overdue	cancer	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT01459380	Oct 2011 → Jun 2016	fallopian tube carcinoma, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma +3	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01495351	Oct 2011 → Feb 2015	plasma cell myeloma	AHS Cancer Control Alberta	Completed	No outcome recorded
Phase 1	NCT01419548	Jul → Nov 2011	neoplasm	National Cancer Institute (NCI)	Withdrawn	No outcome recorded
Phase 1	NCT01366144	Jun 2011 → Nov 2017 overdue	breast carcinoma, cancer of unknown primary site, carcinoma of esophagus, endometrial carcinoma +9	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT01351909	May 2011 → Nov 2016 overdue	breast carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT01281852	Mar 2011 → Feb 2017	cervical adenosquamous carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01264432	Jan 2011 → Nov 2016	fallopian tube carcinoma, ovarian carcinoma, peritoneal carcinomatosis, primary peritoneal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01281150	Jan 2011 → Apr 2015	estrogen-receptor positive breast cancer, female breast carcinoma, male breast carcinoma, triple-negative breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01282333	Jan 2011 → Feb 2013	bladder transitional cell carcinoma, extrahepatic bile duct carcinoma, gallbladder carcinoma, non-small cell lung carcinoma +2	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT01251874	Nov 2010 → Sep 2024 overdue	triple-negative breast carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT01233505	Oct 2010 → Oct 2013	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, cancer of unknown primary site, female breast carcinoma +5	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT01104259	Jul 2010 → Feb 2015	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, male breast carcinoma, triple-negative breast carcinoma	University of Washington	Completed	No outcome recorded
Phase 1	NCT01139970	Jun 2010 → Apr 2014	B-cell adult acute lymphocytic leukemia, B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), T-cell adult acute lymphocytic leukemia, acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent +6	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01145430	Jun 2010 → May 2017	fallopian tube carcinoma, male breast carcinoma, ovarian carcinoma, primary peritoneal carcinoma +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01199224	Jun → Nov 2010	cancer	AbbVie	Completed	Met primary
Phase 1	NCT01154426	May 2010 → Oct 2013	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01085422	Apr 2010 → Jun 2011	prostate cancer	AbbVie	Completed	No outcome recorded
Phase 1	NCT01123876	Mar 2010 → Jan 2015	gastric cancer	AbbVie	Completed	No outcome recorded
Phase 1	NCT01063816	Jan 2010 → Aug 2016	neoplasm	AbbVie	Completed	No outcome recorded
Phase 1	NCT00989651	Oct 2009 → Sep 2016	fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma +11	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01017640	Oct 2009 → May 2016	neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00994071	Sep 2009 → Mar 2013	astrocytoma (excluding glioblastoma), brain stem glioma, ependymoma, medulloblastoma +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00770471	Jul 2009 → Mar 2012	central nervous system neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1	NCT00946335	Jul 2009 → Oct 2011	atypical teratoid rhabdoid tumor, benign meningioma, childhood brain stem glioma, childhood central nervous system germ cell tumor +18	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00892736	Apr 2009 → May 2017	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, basal-like breast carcinoma, fallopian tube carcinoma +4	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01445522	Dec 2008 → Jul 2012	lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00740805	Aug 2008 → Sep 2021 overdue	primary organ-specific lymphoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT00576654	Mar 2008 → Jan 2020	metastatic malignant neoplasm, triple-negative breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00649207	Mar 2008 → Mar 2013	brain neoplasm, metastatic neoplasm	AbbVie	Completed	No outcome recorded
Phase 1	NCT00588991	Feb 2008 → Nov 2016	acquired polycythemia vera, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +13	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00535119	Sep 2007 → Oct 2012	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, hereditary breast ovarian cancer syndrome, neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00553189	Aug 2007 → Feb 2008	cancer, lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00526617	Aug 2007 → Jun 2010	breast cancer, fallopian tube cancer, hepatocellular carcinoma, metastatic melanoma +2	AbbVie	Completed	No outcome recorded
Phase 1	NCT00387608	Jun 2006 → Feb 2008	cancer of unknown primary site, leukemia, lymphoma	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded

Phase 1/212 trials · 1 met primary · 1 missed
Phase 1/2	NCT02412371	Apr 2015 → Aug 2019	non-small cell lung carcinoma	AbbVie	Terminated	No outcome recorded
Phase 1/2	NCT02289690	Oct 2014 → Apr 2019	small cell lung carcinoma	AbbVie	Completed	Missed primary
Phase 1/2	NCT01690598	Nov 2012 → Jan 2015	ovarian carcinoma	Vejle Hospital	Completed	No outcome recorded
Phase 1/2	NCT01711541	Oct 2012 → Feb 2018	head and neck squamous cell carcinoma, oropharyngeal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT01642251	Sep 2012 → Dec 2016	lung large cell carcinoma, small cell lung carcinoma	National Cancer Institute (NCI)	Completed	Met primary
Phase 1/2	NCT01514201	Feb 2012 → Mar 2018	anaplastic astrocytoma, brain stem glioma, fibrillary astrocytoma, giant cell glioblastoma +2	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT01472783	Nov 2011 → Jan 2016	malignant epithelial tumor of ovary	Vejle Hospital	Completed	No outcome recorded
Phase 1/2	NCT01326702	Jul 2011 → Apr 2015	B-cell adult acute lymphocytic leukemia, Burkitt lymphoma, Hodgkin's lymphoma, mixed cellularity, MALT lymphoma +19	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT01386385	Jun 2011 → May 2019 overdue	lung large cell carcinoma, minimally invasive lung adenocarcinoma, squamous cell lung carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT01489865	Jan 2011 → Dec 2018	malignant pancreatic neoplasm	Georgetown University	Completed	No outcome recorded
Phase 1/2	NCT01026493	Jul 2010 → May 2014	central nervous system neoplasm	Radiation Therapy Oncology Group	Completed	No outcome recorded
Phase 1/2	NCT01012817	Nov 2009 → Jan 2019 overdue	fallopian tube carcinoma, metastatic malignant neoplasm, ovarian carcinoma, primary peritoneal carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded

Phase 227 trials · 1 met primary · 12 missed
Phase 2	NCT03044795	Nov 2019 → Nov 2020	cancer	University Medical Center Groningen	Withdrawn	No outcome recorded
Phase 2	NCT03581292	Nov 2018 → Mar 2023 overdue	anaplastic astrocytoma, glioblastoma	Children's Oncology Group	Active not recruiting	Missed primary
Phase 2	NCT03289910	Sep 2018 → May 2023 overdue	acquired polycythemia vera, acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myelomonocytic leukemia +2	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT03032614	Sep 2017 → Mar 2019	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer, ovarian cancer	The University of Texas Health Science Center at San Antonio	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT02921256	Jan 2017 → Apr 2020	rectum adenocarcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT02890355	Oct 2016 → May 2019	pancreatic adenocarcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT02595905	Sep 2016 → Jan 2025	hereditary breast carcinoma, metastatic malignant neoplasm in the brain, triple-negative breast carcinoma	National Cancer Institute (NCI)	Completed	Mixed
Phase 2	NCT02860819	Aug 2016 → Nov 2020	testicular germ cell tumor	National Cancer Institute, Slovakia	Completed	Missed primary
Phase 2	NCT02305758	Dec 2014 → Sep 2017	colorectal cancer	AbbVie	Completed	Missed primary
Phase 2	NCT01827384	Jan 2014 → Jun 2021	cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01818063	Apr 2013 → Mar 2015	triple-negative breast carcinoma	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Completed	No outcome recorded
Phase 2	NCT01657799	Oct 2012 → Jan 2015	non-small cell lung carcinoma	AbbVie	Completed	Missed primary
Phase 2	NCT01638546	Jul 2012 → Jan 2017 overdue	small cell lung carcinoma	National Cancer Institute (NCI)	Active not recruiting	Missed primary
Phase 2	NCT01585805	May 2012 → Dec 2024 overdue	pancreatic adenocarcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2	NCT01540565	Apr 2012 → Jan 2018	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, fallopian tube carcinoma, ovarian carcinoma +1	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01576172	Mar 2012 → Oct 2019	castration-resistant prostate carcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT01560104	Feb 2012 → Sep 2014	non-small cell lung carcinoma	AbbVie	Completed	Missed primary
Phase 2	NCT01506609	Jan 2012 → Dec 2018	breast cancer	AbbVie	Completed	Missed primary
Phase 2	NCT01266447	Feb 2011 → Jan 2016	cervical adenosquamous carcinoma, cervical small cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01306032	Jan 2011 → Dec 2014	fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma, serous adenocarcinoma +1	National Cancer Institute (NCI)	Completed	Mixed
Phase 2	NCT01205828	Aug 2010 → Oct 2014	hepatocellular carcinoma	Georgetown University	Terminated	Missed primary
Phase 2	NCT01193140	Jul 2010 → Nov 2011	—	Abbott	Completed	No outcome recorded
Phase 2	NCT01149083	Jun 2010 → Sep 2024	female breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01042379	Mar 2010 → Dec 2030 expected	HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1	QuantumLeap Healthcare Collaborative	Recruiting	No outcome recorded
Phase 2	NCT01113957	Mar 2010 → Jun 2013	ovarian cancer	AbbVie	Completed	No outcome recorded
Phase 2	NCT01009788	Nov 2009 → Sep 2012	BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer	Steven J Isakoff, MD, PhD	Completed	Missed primary
Phase 2	NCT01051596	Sep 2009 → Jun 2013	colorectal cancer	Georgetown University	Completed	Met primary

Phase 2/31 trial · 1 missed
Phase 2/3	NCT02152982	Dec 2014 → Dec 2021 overdue	gliosarcoma	National Cancer Institute (NCI)	Active not recruiting	Missed primary
Phase 34 trials · 2 met primary · 2 missed
Phase 3	NCT02470585	Jul 2015 → May 2019	ovarian cancer	AbbVie	Terminated	Met primary Stop: Business
Phase 3	NCT02264990	Sep 2014 → Nov 2019	non-small cell lung carcinoma	AbbVie	Completed	Missed primary
Phase 3	NCT02106546	Apr 2014 → Jan 2017	non-small cell squamous lung carcinoma	AbbVie	Completed	Missed primary
Phase 3	NCT02163694	Apr 2014 → Apr 2019	breast cancer	AbbVie	Completed	Met primary
Phase not applicable1 trial
—	NCT02158507	Sep 2014 → Jul 2021	triple-negative breast carcinoma	University of Alabama at Birmingham	Completed	No outcome recorded
Phase not stated1 trial
—	NCT02985658	—	hereditary breast carcinoma, triple-negative breast carcinoma	University of Washington	No longer available	No outcome recorded
Comparator or background therapy3 trials
Phase 2	NCT00804908 Comparator	Feb 2009 → Jan 2016	metastatic melanoma, skin cancer	AbbVie	Completed	No outcome recorded
Phase 3	NCT02032277 Comparator	Apr 2014 → Mar 2016	triple-negative breast carcinoma	AbbVie	Completed	No outcome recorded
—	NCT03123211 Background	—	ovarian serous adenocarcinoma, triple-negative breast carcinoma	AbbVie	No longer available	No outcome recorded

News releases announcing trial results or a regulatory action · 3

Date	Issuer	Release
2017-04-19	AbbVie	Results AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer abbvie.com ↗ AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor did not meet their primary endpoints.
2016-11-04	AbbVie	Regulatory AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer abbvie.com ↗
2015-06-01	AbbVie	Results AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting abbvie.com ↗ Veliparib showed interesting results when combined with chemotherapy in a subset of patients with smoking history.

All press releases naming this drug 5 releases

Date	Issuer	Release
2017-04-19	AbbVie	AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer abbvie.com ↗
2016-11-04	AbbVie	AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer abbvie.com ↗
2015-06-01	AbbVie	AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting abbvie.com ↗
2014-04-15	AbbVie	AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer abbvie.com ↗
2014-01-15	AbbVie	AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer abbvie.com ↗

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 108 sources stand behind the page.

Field	Value	Cited text
Known as	Veliparib	“The experimental cancer treatment drug ABT-888 (Veliparib) works by preventing deoxyribonucleic acid (DNA) repair in tumor cells.” NCT01306032 ↗ 87 “A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan” PMID 21795476 ↗ Jul 2011 “ABT-888 (Veliparib)” NCT01495351 ↗ NCT03061188 ↗ NCT01233505 ↗ NCT01281852 ↗ NCT01104259 ↗ NCT01472783 ↗ NCT01617928 ↗ NCT02264990 ↗ NCT01282333 ↗ Show 77 more sources
Known as	ABT-888	“Veliparib (ABT-888) is a potent PARP 1/2 inhibitor with clinical evidence of potentiation of antitumor activity in combination with cisplatin in breast cancer gene (BRCA)...” NCT02723864 ↗ 29 “PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of veliparib (ABT-888) in combination with capecitabine and temozolomide in patients with advanced...” NCT02831179 ↗ “The purpose of this study is to investigate the effect of combined topotecan and veliparib (ABT888) treatment in relapsed ovarian cancer with tumor progression and negative or...” NCT01690598 ↗ “A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small...” PMID 26433581 ↗ Oct 2015 “Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay...” NCT03044795 ↗ “Veliparib (ABT888) Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer” NCT01472783 ↗ “PURPOSE: Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and PARP-2.” PMID 27709282 ↗ Oct 2016 “This study assessed the efficacy and safety of low dose oral PARP inhibitor veliparib (ABT-888) and temozolomide (TMZ)” PMID 24764124 ↗ Apr 2014 “Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.” PMID 28243955 ↗ Feb 2017 “To determine the maximum-tolerated dose (MTD) of ABT-888 (veliparib) in combination with bendamustine” NCT01326702 ↗ “ABT-888 (veliparib) 10 mg administered orally twice a day on days 1 to 5” NCT01266447 ↗ Show 19 more sources
Known as	ABT-888, veliparib	“ABT-888, veliparib” NCT01113957 ↗ 1 “ABT-888, veliparib” NCT01085422 ↗
Known as	NSC 737664	“veliparib (ABT-888) (NSC 737664)” NCT01149083 ↗
Known as	PARP-1 INHIBITOR ABT-888	ChEMBL registry synonym — accepted as the source's own label CHEMBL506871 ↗
Known as	UNII-01O4K0631N	ChEMBL registry synonym — accepted as the source's own label CHEMBL506871 ↗
Known as	Veliparib (ABT-888)	“Veliparib (ABT-888)” NCT02158507 ↗
Action	Inhibit	“ABT-888 is an oral PARP inhibitor” NCT00553189 ↗
Modality	Small molecule	— CHEMBL506871 ↗
Route	Oral	“veliparib orally (PO)” NCT00535119 ↗
Target	PARP1	“To develop assays to detect trapping of PARP1 and 2 in tumor biopsy tissue in response to treatment with irinotecan plus a PARP inhibitor, in this case ABT-888.” NCT00576654 ↗